Daiichi Sankyo Co. Ltd. Ads (DSNKY) 24.5500 $DSNKY
Daiichi Sankyo webcast presentation now available for on-demand viewing: dbVIC - Deutsche Bank ADR Virtual Investor Conference
PR Newswire - Mon Jun 13, 7:30AM CDT
Company invites individual and institutional investors, as well as advisors, to log-on to view the presentation
DB: 16.81 (+0.51)
International companies to host live webcasts at Deutsche Bank's June 9th and 10th Depositary Receipts Virtual Investor Conference
PR Newswire Europe - Mon Jun 06, 8:01AM CDT
Deutsche Bank today announced the lineup for its June 9(th) and 10(th) Depositary Receipts Virtual Investor Conference ("dbVIC"
, featuring live webcast presentations from international companies with American Depositary Receipt (ADR) programs in the US.
SNN: 34.06 (+0.20), DL: 9.88 (+0.04), HCM: 13.73 (+0.03), DB: 16.81 (+0.51)
Daiichi Sankyo to present at the dbVIC - Deutsche Bank ADR Virtual Investor Conference on Thursday, June 9th, 2016
PR Newswire - Mon Jun 06, 7:30AM CDT
Company invites individual and institutional investors, as well as advisors, to attend a virtual event
DB: 16.81 (+0.51)
Daiichi Sankyo Provides Update on HER3-Lung Study of Patritumab in Non-Small Cell Lung Cancer (NSCLC)
PR Newswire - Tue May 31, 7:30AM CDT
Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced that the two-part phase 3 HER3-Lung study of patritumab will not proceed into the second part. This decision followed the recommendation of an independent data monitoring committee (DMC) that concluded that the first part of the study (Part A) did not meet the pre-defined efficacy criteria required to proceed with Part B of the study. There were no safety concerns identified by the DMC.
Nitto Signs Partnership Agreement with Daiichi Sankyo
BusinessWire - Tue May 10, 8:00AM CDT
Japan's leading diversified materials manufacturer Nitto Denko Corporation (TOKYO:6988)(ISIN:JP3684000007) today announced the signing of a partnership agreement with global pharmaceutical company Daiichi Sankyo Company, Ltd. (hereafter "Daiichi Sankyo" that will utilize Nitto's proprietary PassPort(R) active transdermal drug delivery technology.
Global Hypertension Drugs Market 2016-2020 - Key Vendors are Actelion, AstraZeneca, Boehringer Ingelheim, Daiichi Sankyo Company, Novartis AG & Sanofi SA - Research and Markets
BusinessWire - Wed Apr 27, 8:41AM CDT
Research and Markets has announced the addition of the "Global Hypertension Drugs Market 2016-2020" report to their offering.
NVS: 79.46 (+0.79)
Daiichi Sankyo, Inc. To Establish New U.S. Headquarters in Basking Ridge, New Jersey
PR Newswire - Mon Apr 18, 9:31AM CDT
Daiichi Sankyo, Inc., the U.S. subsidiary of Daiichi Sankyo Company, Ltd., today announced that it will establish a new U.S. headquarters, co-locating its commercial and development divisions in Basking Ridge, NJ. The move is part of an ongoing effort to realize efficiencies and continue collaboration between the business segments, enabling innovation in its existing and emerging therapeutic areas such as cardiology, oncology, pain and other areas where there are unmet medical needs.
Atherosclerosis Pipeline: H2 2015 World Market Research Report
PR Newswire - Wed Mar 09, 6:30AM CST
Market research report titled "Atherosclerosis - Pipeline Review, H2 2015" provides an overview of the Atherosclerosis's therapeutic pipeline and enhances decision making capabilities to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
JNJ: 116.18 (-0.36), VCEL: 2.23 (-0.06), KNMD: (), OPK: 9.70 (+0.51), GILD: 81.79 (-1.20), MRK: 56.25 (+0.11), AZN: 28.64 (+0.22), OMER: 10.87 (-0.01)
Non-Small Cell Lung Cancer - Pipeline Review 2015
M2 - Tue Feb 09, 9:56AM CST
Research and Markets (http://www.researchandmarkets.com/research/pnx7gl/nonsmall_cell) has announced the addition of the "Non-Small Cell Lung Cancer - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Non-Small Cell Lung Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Non-Small Cell Lung Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Non-Small Cell Lung Cancer Overview - Therapeutics Development - Pipeline Products for Non-Small Cell Lung Cancer - Overview - Pipeline Products for Non-Small Cell Lung Cancer - Comparative Analysis - Non-Small Cell Lung Cancer - Therapeutics under Development by Companies - Non-Small Cell Lung Cancer - Therapeutics under Investigation by Universities/Institutes - Non-Small Cell Lung Cancer - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Non-Small Cell Lung Cancer - Products under Development by Companies - Non-Small Cell Lung Cancer - Products under Investigation by Universities/Institutes - Non-Small Cell Lung Cancer - Companies Involved in Therapeutics Development Companies Mentioned: - Arch Biopartners, Inc. - Ariad Pharmaceuticals, Inc. - Arog Pharmaceuticals, Inc. - ArQule, Inc. - Array BioPharma Inc. - Arrien Pharmaceuticals, LLC - Ascenta Therapeutics, Inc. - Astellas Pharma Inc. - Astex Pharmaceuticals, Inc. - AstraZeneca Plc - ATLAB Pharma SAS - AVEO Pharmaceuticals, Inc. - Axelar AB - CTI BioPharma Corp. - CureFAKtor Pharmaceuticals, LLC - CureVac GmbH - CytRx Corporation - Daiichi Sankyo Company, Limited - DanDrit Biotech A/S - Viralytics Ltd. - XBiotech USA, Inc. - Zhejiang BetaPharma Co., Ltd. - Zyngenia, Inc. - (200 Others) For more information visit http://www.researchandmarkets.com/research/pn...small_cell
AZN: 28.64 (+0.22), ACH: 7.72 (+0.04), CYTR: 2.24 (-0.03), AVEO: 0.98 (-0.03), ARQL: 1.75 (unch), CTIC: 0.40 (-0.01), ARRY: 3.35 (+0.07)
Stroke - Pipeline Review 2015
M2 - Tue Feb 09, 9:56AM CST
Research and Markets (http://www.researchandmarkets.com/research/23dsxv/stroke_pipeline) has announced the addition of the "Stroke - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Stroke, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Stroke and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Stroke Overview - Therapeutics Development - Pipeline Products for Stroke - Overview - Pipeline Products for Stroke - Comparative Analysis - Stroke - Therapeutics under Development by Companies - Stroke - Therapeutics under Investigation by Universities/Institutes - Stroke - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Stroke - Products under Development by Companies - Stroke - Products under Investigation by Universities/Institutes - Stroke - Companies Involved in Therapeutics Development Companies Mentioned Include: - AB Science SA - Acorda Therapeutics, Inc. - Acticor Biotech - Biogen, Inc. - BioTime, Inc. - Cardax Pharmaceuticals, Inc. - Cellular Biomedicine Group, Inc. - CHA Bio & Diostech Co., Ltd. - CoDa Therapeutics, Inc. - D-Pharm Ltd. - Daiichi Sankyo Company, Limited - DiaMedica Inc. - Digna Biotech, S.L. - NoNO, Inc. - Omeros Corporation - Panacea Pharmaceuticals, Inc. - PharmatrophiX, Inc. - Pharmicell Co., Ltd. - Phoenix Biotechnology, Inc. - Phylogica Limited - PhytoHealth Corporation - Pozen, Inc. - Primary Peptides, Inc. - (Others) For more information visit http://www.researchandmarkets.com/research/23...e_pipeline
ACOR: 25.08 (-0.23), POZN: 5.94 (-0.43), CBMG: 14.30 (-0.85), OMER: 10.87 (-0.01)
Global Obesity Pipeline Review, H2 2015 - Therapeutics Under Development by Leading Companies and Universities
M2 - Tue Feb 09, 8:28AM CST
Research and Markets (http://www.researchandmarkets.com/research/4fs2cn/obesity) has announced the addition of the "Obesity - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Multiple Myeloma (Kahler Disease), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Obesityand special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - ObesityOverview - Therapeutics Development - Pipeline Products for Obesity - Overview - Pipeline Products for Obesity - Comparative Analysis - Obesity - Therapeutics under Development by Companies - Obesity - Therapeutics under Investigation by Universities/Institutes - Obesity - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Obesity - Products under Development by Companies - Obesity - Products under Investigation by Universities/Institutes - Obesity - Companies Involved in Therapeutics Development Companies Mentioned - Sample List of the 35 Companies Featured - Abeome Corporation - Advinus Therapeutics Ltd. - Aegis Therapeutics, LLC - Akron Molecules AG - Alize Pharma SAS - Amabiotics SAS - Ambrx, Inc. - Amgen Inc. - Arena Pharmaceuticals, Inc. - Arrien Pharmaceuticals, LLC - AstraZeneca Plc - Asubio Pharma Co., Ltd. - AtheroNova Inc. - Avaxia Biologics, Inc. - BioLingus AG - BioRestorative Therapies, Inc. - BioTime, Inc. - Boehringer Ingelheim GmbH - Braasch Biotech LLC - Bristol-Myers Squibb Company - Camurus AB - Carmot Therapeutics, Inc. - Chronos Therapeutics Limited - CohBar, Inc. - CoMentis, Inc. - Daiichi Sankyo Company, Limited - Deltanoid Pharmaceuticals Inc. - Diabetica Limited - DiscoveryBiomed, Inc. - Eisai Co., Ltd. - Eli Lilly and Company - Esperion Therapeutics, Inc. - Euroscreen S.A. - F. Hoffmann-La Roche Ltd. - FibroGen, Inc. For more information visit http://www.researchandmarkets.com/research/4fs2cn/obesity
AMBX: (), AMGN: 149.42 (-1.23), LLY: 72.57 (-0.71), BMY: 71.25 (+0.29), ESPR: 16.41 (-0.93), AZN: 28.64 (+0.22), FGEN: 15.68 (-0.27), ARNA: 1.87 (-0.03)
Crohn's Disease (Regional Enteritis) - Pipeline Review Report H2 2015
M2 - Tue Feb 09, 8:23AM CST
Research and Markets (http://www.researchandmarkets.com/research/crzbr7/crohns_disease) has announced the addition of the "Crohn's Disease (Regional Enteritis) - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Multiple Myeloma (Kahler Disease), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Crohn's Disease (Regional Enteritis)and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Crohn's Disease (Regional Enteritis)Overview - Therapeutics Development - Pipeline Products for Crohn's Disease (Regional Enteritis)- Overview - Pipeline Products for Crohn's Disease (Regional Enteritis)- Comparative Analysis - Crohn's Disease (Regional Enteritis)- Therapeutics under Development by Companies - Crohn's Disease (Regional Enteritis)- Therapeutics under Investigation by Universities/Institutes - Crohn's Disease (Regional Enteritis)- Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Crohn's Disease (Regional Enteritis)- Products under Development by Companies - Crohn's Disease (Regional Enteritis)- Products under Investigation by Universities/Institutes - Crohn's Disease (Regional Enteritis)- Companies Involved in Therapeutics Development Companies Mentioned - Sample List - 4D Pharma Plc - 4SC AG - AB Science SA - AbbVie Inc. - Alba Therapeutics Corporation - Alfa Wassermann S.p.A - Allozyne, Inc. - Altheus Therapeutics, Inc. - Amgen Inc. - Ampio Pharmaceuticals, Inc. - Arena Pharmaceuticals, Inc. - Avaxia Biologics, Inc. - BioAtla, LLC - BIOCAD - BioLingus AG - Bionovis SA - BioTherapeutics Inc. - Boehringer Ingelheim GmbH - Calypso Biotech SA - Celgene Corporation - Celltrion, Inc. - ChemoCentryx, Inc. - ChironWells GmbH - Chong Kun Dang Pharmaceutical Corp. - CLL Pharma - Commence Bio, Inc. - Daiichi Sankyo Company, Limited - DBV Technologies S.A. - Eisai Co., Ltd. - Eli Lilly and Company - Emergent BioSolutions Inc. - Enterome Bioscience SA - Enzo Biochem, Inc. - Epirus Biopharmaceuticals, Inc. - F. Hoffmann-La Roche Ltd. For more information visit http://www.researchandmarkets.com/research/cr...ns_disease
EBS: 39.32 (unch), AMGN: 149.42 (-1.23), AMPE: 3.33 (+0.11), LLY: 72.57 (-0.71), ENZ: 5.68 (+0.01), CCXI: 4.48 (-0.09), ABBV: 59.98 (-0.13), ARNA: 1.87 (-0.03), CELGZ: 1.44 (-0.01)
Head And Neck Cancer Therapeutics Pipeline Review, H2 2015
M2 - Tue Feb 09, 6:35AM CST
Research and Markets (http://www.researchandmarkets.com/research/bls9lh/head_and_neck) has announced the addition of the "Head And Neck Cancer - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Head And Neck Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Head And Neck Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Head And Neck Cancer Overview - Therapeutics Development - Pipeline Products for Head And Neck Cancer - Overview - Pipeline Products for Head And Neck Cancer - Comparative Analysis - Head And Neck Cancer - Therapeutics under Development by Companies - Head And Neck Cancer - Therapeutics under Investigation by Universities/Institutes - Head And Neck Cancer - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Head And Neck Cancer - Products under Development by Companies - Head And Neck Cancer - Products under Investigation by Universities/Institutes - Head And Neck Cancer - Companies Involved in Therapeutics Development - 4SC AG - AB Science SA - AbbVie Inc. - Acceleron Pharma, Inc. - Advaxis, Inc. - Alchemia Limited - Altor BioScience Corporation - Ambrx, Inc. - Amgen Inc. - ANP Technologies, Inc. - arGEN-X BV - ArQule, Inc. - Ascenta Therapeutics, Inc. - Astellas Pharma Inc. - Astex Pharmaceuticals, Inc. - AstraZeneca Plc - ATLAB Pharma SAS - AVEO Pharmaceuticals, Inc. - Bayer AG - Bexion Pharmaceuticals, LLC. - BIND Therapeutics, Inc. - Bio-Path Holdings, Inc. - BioDiem Ltd - Bionovis SA - Biotest AG - Boehringer Ingelheim GmbH - Boston Biomedical, Inc. - Bristol-Myers Squibb Company - CEL-SCI Corporation - Celgene Corporation - Cell Medica Limited - Cellceutix Corporation - Celldex Therapeutics, Inc. - Celltrion, Inc. - Centrose LLC - Cristal Therapeutics - Critical Outcome Technologies Inc. - CTI BioPharma Corp. - CytomX Therapeutics, Inc. - Daiichi Sankyo Company, Limited - EcoBiotics Limited For more information visit http://www.researchandmarkets.com/research/bl...d_and_neck
CVM: 0.46 (-0.01), AMBX: (), CLDX: 4.46 (+0.05), ARQL: 1.75 (unch), CTIC: 0.40 (-0.01), CTMX: 9.63 (+0.19), ABBV: 59.98 (-0.13), XLRN: 33.73 (-1.14), ADXS: 8.38 (-0.13), AMGN: 149.42 (-1.23), BIND: 0.44 (-0.02), BMY: 71.25 (+0.29), BPTH: 2.18 (+0.20), AZN: 28.64 (+0.22), AVEO: 0.98 (-0.03), CELGZ: 1.44 (-0.01)
Dyslipidemia Pipeline Review, H2 2015
M2 - Fri Feb 05, 6:27AM CST
Research and Markets (http://www.researchandmarkets.com/research/bbj35n/dyslipidemia) has announced the addition of the "Dyslipidemia - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Dyslipidemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Dyslipidemia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Dyslipidemia Overview - Therapeutics Development - Pipeline Products for Dyslipidemia - Overview - Pipeline Products for Dyslipidemia - Comparative Analysis - Dyslipidemia - Therapeutics under Development by Companies - Dyslipidemia - Therapeutics under Investigation by Universities/Institutes - Dyslipidemia - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Dyslipidemia - Products under Development by Companies - Dyslipidemia - Products under Investigation by Universities/Institutes - Dyslipidemia - Companies Involved in Therapeutics Development (Partial List) - Acasti Pharma Inc. - Allergan Plc - Alnylam Pharmaceuticals, Inc. - Amgen Inc. - Arbutus Biopharma Corporation - Arisaph Pharmaceuticals, Inc. - Astellas Pharma Inc. - AstraZeneca Plc - AtheroNova Inc. - BASF SE - BCWorld Pharm Co. Ltd. - Cadila Pharmaceuticals Ltd. - Cardax Pharmaceuticals, Inc. - Catabasis Pharmaceuticals, Inc. - Cerenis Therapeutics Holding SA - Chong Kun Dang Pharmaceutical Corp. - CJ HealthCare Corp. - Connexios Life Sciences Pvt. Ltd. - CymaBay Therapeutics, Inc. - Daewoong Pharmaceutical Co., Ltd. - Daiichi Sankyo Company, Limited - Debiopharm International S.A. - Eli Lilly and Company - Gemphire Therapeutics Inc. - Genfit SA - GlaxoSmithKline Plc - HanAll Biopharma Co., Ltd. - Hanmi Pharmaceuticals, Co. Ltd. - Huons Co., Ltd. - Hyundai Pharmaceutical Co., Ltd. - Innovent Biologics, Inc. - IPCA Laboratories Limited - Isis Pharmaceuticals, Inc. - Jeil Pharmaceutical Co., Ltd. - Jenrin Discovery, Inc. For more information visit http://www.researchandmarkets.com/research/bb...slipidemia
AMGN: 149.42 (-1.23), LLY: 72.57 (-0.71), GSK: 41.65 (+0.16), AGN: 231.55 (-3.71), ABUS: 3.17 (-0.09), ACST: 1.47 (-0.04), ISIS: 57.56 (-0.28), AZN: 28.64 (+0.22), CBAY: 1.69 (-0.06)
Cancer Pain Pipeline Review, H2 2015
M2 - Fri Feb 05, 4:26AM CST
Research and Markets (http://www.researchandmarkets.com/research/3tjd78/cancer_pain) has announced the addition of the "Cancer Pain - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Cancer Pain, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cancer Pain and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Cancer Pain Overview - Therapeutics Development - Pipeline Products for Cancer Pain - Overview - Pipeline Products for Cancer Pain - Comparative Analysis - Cancer Pain - Therapeutics under Development by Companies - Cancer Pain - Therapeutics under Investigation by Universities/Institutes - Cancer Pain - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Cancer Pain - Products under Development by Companies - Cancer Pain - Products under Investigation by Universities/Institutes - Cancer Pain - Companies Involved in Therapeutics Development - Amgen Inc. - Amorsa Therapeutics Inc. - AngioChem Inc. - Aphios Corporation - AstraZeneca Plc - BCN Peptides, S.A. - Benitec Biopharma Limited - BioDelivery Sciences International, Inc. - ChironWells GmbH - Daiichi Sankyo Company, Limited - Fujimoto Pharmaceutical Corporation - Grunenthal GmbH - GW Pharmaceuticals Plc - Hisamitsu Pharmaceutical Co., Inc. - Immupharma Plc - IntelGenx Corp. - Kolon Life Science, Inc. - Nektar Therapeutics - Neurocentrx Pharma Ltd. - Orion Oyj - Pain Therapeutics, Inc. - Pfizer Inc. - Pharmaleads - PsychoGenics, Inc. - Recordati S.p.A. - Ribomic Inc. - Virobay Inc. - WEX Pharmaceuticals Inc. - Winston Pharmaceuticals, Inc. - Zynerba Pharmaceuticals, Inc. For more information visit http://www.researchandmarkets.com/research/3t...ancer_pain
BDSI: 2.44 (+0.08), PFE: 34.75 (+0.25), AMGN: 149.42 (-1.23), ZYNE: 7.37 (-0.10), NKTR: 14.98 (-0.23), AZN: 28.64 (+0.22), VBAY: (), PTIE: 2.07 (-0.01)
Global Influenza A Infections Clinical Trials Review, H2, 2015
M2 - Thu Feb 04, 5:30AM CST
Research and Markets (http://www.researchandmarkets.com/research/2qjxfz/influenza_a) has announced the addition of the "Influenza A Infections Global Clinical Trials Review, H2, 2015" report to their offering. Influenza A Infections Global Clinical Trials Review, H2, 2015" provides an overview of Influenza A Infections clinical trials scenario. This report provides top line data relating to the clinical trials on Influenza A Infections. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). Key Topics Covered: - List of Tables - List of Figures - Report Guidance - Clinical Trials by Region - Clinical Trials and Average Enrollment by Country - Top Five Countries Contributing to Clinical Trials in Asia-Pacific - Top Five Countries Contributing to Clinical Trials in Europe - Top Countries Contributing to Clinical Trials in North America - Top Countries Contributing to Clinical Trials in Middle East and Africa - Top Five Countries Contributing to Clinical Trials in Central and South America - Clinical Trials by G7 Countries: Proportion of Influenza A Infections to Infectious Disease Clinical Trials - Clinical Trials by Phase in G7 Countries - Clinical Trials in G7 Countries by Trial Status - Clinical Trials by E7 Countries: Proportion of Influenza A Infections to Infectious Disease Clinical Trials - Clinical Trials by Phase in E7 Countries - Clinical Trials in E7 Countries by Trial Status - Clinical Trials by Phase - In Progress Trials by Phase - Clinical Trials by Trial Status - Clinical Trials by End Point Status - Subjects Recruited Over a Period of Time - Clinical Trials by Sponsor Type - Prominent Sponsors - Top Companies Participating in Influenza A Infections Therapeutics Clinical Trials - Prominent Drugs - Latest Clinical Trials News on Influenza A Infections - Clinical Trial Profile Snapshots Companies Mentioned - GlaxoSmithKline Plc - Novartis AG - Sanofi - Johnson & Johnson - AstraZeneca Plc - Microgen Scientific Industrial Company for Immunobiological Medicines - F. Hoffmann-La Roche Ltd. - Daiichi Sankyo Company, Limited - Altimmune, Inc. - Nanotherapeutics, Inc. For more information visit http://www.researchandmarkets.com/research/2q...nfluenza_a
JNJ: 116.18 (-0.36), AZN: 28.64 (+0.22), GSK: 41.65 (+0.16), NVS: 79.46 (+0.79)
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Pipeline Review, H2 2015
M2 - Thu Feb 04, 5:02AM CST
Research and Markets (http://www.researchandmarkets.com/research/trfcb9/acute_lymphocytic) has announced the addition of the "Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Overview - Therapeutics Development - Pipeline Products for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Overview - Pipeline Products for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Comparative Analysis - Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Therapeutics under Development by Companies - Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Therapeutics under Investigation by Universities/Institutes - Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Products under Development by Companies - Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Products under Investigation by Universities/Institutes - Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Companies Involved in Therapeutics Development Companies Mentioned - Partial List - 4SC AG - AbbVie Inc. - Actinium Pharmaceuticals, Inc. - Affimed Therapeutics AG - Altor BioScience Corporation - Amgen Inc. - Atara Biotherapeutics, Inc. - Baxalta Incorporated - Bellicum Pharmaceuticals, Inc. - Bexion Pharmaceuticals, LLC. - Bio-Path Holdings, Inc. - BioSight Ltd. - Bristol-Myers Squibb Company - Calithera Biosciences, Inc. - Cantargia AB - Celator Pharmaceuticals, Inc. - Cellectis S.A. - Cellular Biomedicine Group, Inc. - Ceronco Biosciences - Constellation Pharmaceuticals, Inc. - Cyclacel Pharmaceuticals, Inc. - Daiichi Sankyo Company, Limited - DiNonA Inc. - Effimune SAS - Eli Lilly and Company - Epirus Biopharmaceuticals, Inc. - EpiZyme, Inc. - Erytech Pharma SA - Eureka Therapeutics, Inc. - Fate Therapeutics, Inc. - Formula Pharmaceuticals, Inc. - Gamida Cell Ltd. - GlaxoSmithKline Plc - Hangzhou Minsheng Pharmaceutical Group Co.,Ltd For more information visit http://www.researchandmarkets.com/research/tr...ymphocytic
FATE: 1.89 (-0.11), AMGN: 149.42 (-1.23), EPZM: 10.92 (-0.04), LLY: 72.57 (-0.71), ATRA: 21.56 (+0.50), GSK: 41.65 (+0.16), BMY: 71.25 (+0.29), ATNM: 1.75 (-0.02), CYCC: 5.39 (+0.27), BLCM: 12.49 (-0.33), BPTH: 2.18 (+0.20), CALA: 4.24 (-0.02), ABBV: 59.98 (-0.13), BXLT: 46.02 (-0.18), CBMG: 14.30 (-0.85)
Daiichi Sankyo webcast presentation now available for on-demand viewing: dbVIC - Deutsche Bank ADR Virtual Investor Conference
PR Newswire - Mon Jun 13, 7:30AM CDT
Company invites individual and institutional investors, as well as advisors, to log-on to view the presentation
DB: 16.81 (+0.51)
International companies to host live webcasts at Deutsche Bank's June 9th and 10th Depositary Receipts Virtual Investor Conference
PR Newswire Europe - Mon Jun 06, 8:01AM CDT
Deutsche Bank today announced the lineup for its June 9(th) and 10(th) Depositary Receipts Virtual Investor Conference ("dbVIC"
, featuring live webcast presentations from international companies with American Depositary Receipt (ADR) programs in the US. SNN: 34.06 (+0.20), DL: 9.88 (+0.04), HCM: 13.73 (+0.03), DB: 16.81 (+0.51)
Daiichi Sankyo to present at the dbVIC - Deutsche Bank ADR Virtual Investor Conference on Thursday, June 9th, 2016
PR Newswire - Mon Jun 06, 7:30AM CDT
Company invites individual and institutional investors, as well as advisors, to attend a virtual event
DB: 16.81 (+0.51)
Daiichi Sankyo Provides Update on HER3-Lung Study of Patritumab in Non-Small Cell Lung Cancer (NSCLC)
PR Newswire - Tue May 31, 7:30AM CDT
Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced that the two-part phase 3 HER3-Lung study of patritumab will not proceed into the second part. This decision followed the recommendation of an independent data monitoring committee (DMC) that concluded that the first part of the study (Part A) did not meet the pre-defined efficacy criteria required to proceed with Part B of the study. There were no safety concerns identified by the DMC.
Nitto Signs Partnership Agreement with Daiichi Sankyo
BusinessWire - Tue May 10, 8:00AM CDT
Japan's leading diversified materials manufacturer Nitto Denko Corporation (TOKYO:6988)(ISIN:JP3684000007) today announced the signing of a partnership agreement with global pharmaceutical company Daiichi Sankyo Company, Ltd. (hereafter "Daiichi Sankyo"
that will utilize Nitto's proprietary PassPort(R) active transdermal drug delivery technology. Global Hypertension Drugs Market 2016-2020 - Key Vendors are Actelion, AstraZeneca, Boehringer Ingelheim, Daiichi Sankyo Company, Novartis AG & Sanofi SA - Research and Markets
BusinessWire - Wed Apr 27, 8:41AM CDT
Research and Markets has announced the addition of the "Global Hypertension Drugs Market 2016-2020" report to their offering.
NVS: 79.46 (+0.79)
Daiichi Sankyo, Inc. To Establish New U.S. Headquarters in Basking Ridge, New Jersey
PR Newswire - Mon Apr 18, 9:31AM CDT
Daiichi Sankyo, Inc., the U.S. subsidiary of Daiichi Sankyo Company, Ltd., today announced that it will establish a new U.S. headquarters, co-locating its commercial and development divisions in Basking Ridge, NJ. The move is part of an ongoing effort to realize efficiencies and continue collaboration between the business segments, enabling innovation in its existing and emerging therapeutic areas such as cardiology, oncology, pain and other areas where there are unmet medical needs.
Atherosclerosis Pipeline: H2 2015 World Market Research Report
PR Newswire - Wed Mar 09, 6:30AM CST
Market research report titled "Atherosclerosis - Pipeline Review, H2 2015" provides an overview of the Atherosclerosis's therapeutic pipeline and enhances decision making capabilities to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
JNJ: 116.18 (-0.36), VCEL: 2.23 (-0.06), KNMD: (), OPK: 9.70 (+0.51), GILD: 81.79 (-1.20), MRK: 56.25 (+0.11), AZN: 28.64 (+0.22), OMER: 10.87 (-0.01)
Non-Small Cell Lung Cancer - Pipeline Review 2015
M2 - Tue Feb 09, 9:56AM CST
Research and Markets (http://www.researchandmarkets.com/research/pnx7gl/nonsmall_cell) has announced the addition of the "Non-Small Cell Lung Cancer - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Non-Small Cell Lung Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Non-Small Cell Lung Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Non-Small Cell Lung Cancer Overview - Therapeutics Development - Pipeline Products for Non-Small Cell Lung Cancer - Overview - Pipeline Products for Non-Small Cell Lung Cancer - Comparative Analysis - Non-Small Cell Lung Cancer - Therapeutics under Development by Companies - Non-Small Cell Lung Cancer - Therapeutics under Investigation by Universities/Institutes - Non-Small Cell Lung Cancer - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Non-Small Cell Lung Cancer - Products under Development by Companies - Non-Small Cell Lung Cancer - Products under Investigation by Universities/Institutes - Non-Small Cell Lung Cancer - Companies Involved in Therapeutics Development Companies Mentioned: - Arch Biopartners, Inc. - Ariad Pharmaceuticals, Inc. - Arog Pharmaceuticals, Inc. - ArQule, Inc. - Array BioPharma Inc. - Arrien Pharmaceuticals, LLC - Ascenta Therapeutics, Inc. - Astellas Pharma Inc. - Astex Pharmaceuticals, Inc. - AstraZeneca Plc - ATLAB Pharma SAS - AVEO Pharmaceuticals, Inc. - Axelar AB - CTI BioPharma Corp. - CureFAKtor Pharmaceuticals, LLC - CureVac GmbH - CytRx Corporation - Daiichi Sankyo Company, Limited - DanDrit Biotech A/S - Viralytics Ltd. - XBiotech USA, Inc. - Zhejiang BetaPharma Co., Ltd. - Zyngenia, Inc. - (200 Others) For more information visit http://www.researchandmarkets.com/research/pn...small_cell
AZN: 28.64 (+0.22), ACH: 7.72 (+0.04), CYTR: 2.24 (-0.03), AVEO: 0.98 (-0.03), ARQL: 1.75 (unch), CTIC: 0.40 (-0.01), ARRY: 3.35 (+0.07)
Stroke - Pipeline Review 2015
M2 - Tue Feb 09, 9:56AM CST
Research and Markets (http://www.researchandmarkets.com/research/23dsxv/stroke_pipeline) has announced the addition of the "Stroke - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Stroke, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Stroke and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Stroke Overview - Therapeutics Development - Pipeline Products for Stroke - Overview - Pipeline Products for Stroke - Comparative Analysis - Stroke - Therapeutics under Development by Companies - Stroke - Therapeutics under Investigation by Universities/Institutes - Stroke - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Stroke - Products under Development by Companies - Stroke - Products under Investigation by Universities/Institutes - Stroke - Companies Involved in Therapeutics Development Companies Mentioned Include: - AB Science SA - Acorda Therapeutics, Inc. - Acticor Biotech - Biogen, Inc. - BioTime, Inc. - Cardax Pharmaceuticals, Inc. - Cellular Biomedicine Group, Inc. - CHA Bio & Diostech Co., Ltd. - CoDa Therapeutics, Inc. - D-Pharm Ltd. - Daiichi Sankyo Company, Limited - DiaMedica Inc. - Digna Biotech, S.L. - NoNO, Inc. - Omeros Corporation - Panacea Pharmaceuticals, Inc. - PharmatrophiX, Inc. - Pharmicell Co., Ltd. - Phoenix Biotechnology, Inc. - Phylogica Limited - PhytoHealth Corporation - Pozen, Inc. - Primary Peptides, Inc. - (Others) For more information visit http://www.researchandmarkets.com/research/23...e_pipeline
ACOR: 25.08 (-0.23), POZN: 5.94 (-0.43), CBMG: 14.30 (-0.85), OMER: 10.87 (-0.01)
Global Obesity Pipeline Review, H2 2015 - Therapeutics Under Development by Leading Companies and Universities
M2 - Tue Feb 09, 8:28AM CST
Research and Markets (http://www.researchandmarkets.com/research/4fs2cn/obesity) has announced the addition of the "Obesity - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Multiple Myeloma (Kahler Disease), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Obesityand special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - ObesityOverview - Therapeutics Development - Pipeline Products for Obesity - Overview - Pipeline Products for Obesity - Comparative Analysis - Obesity - Therapeutics under Development by Companies - Obesity - Therapeutics under Investigation by Universities/Institutes - Obesity - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Obesity - Products under Development by Companies - Obesity - Products under Investigation by Universities/Institutes - Obesity - Companies Involved in Therapeutics Development Companies Mentioned - Sample List of the 35 Companies Featured - Abeome Corporation - Advinus Therapeutics Ltd. - Aegis Therapeutics, LLC - Akron Molecules AG - Alize Pharma SAS - Amabiotics SAS - Ambrx, Inc. - Amgen Inc. - Arena Pharmaceuticals, Inc. - Arrien Pharmaceuticals, LLC - AstraZeneca Plc - Asubio Pharma Co., Ltd. - AtheroNova Inc. - Avaxia Biologics, Inc. - BioLingus AG - BioRestorative Therapies, Inc. - BioTime, Inc. - Boehringer Ingelheim GmbH - Braasch Biotech LLC - Bristol-Myers Squibb Company - Camurus AB - Carmot Therapeutics, Inc. - Chronos Therapeutics Limited - CohBar, Inc. - CoMentis, Inc. - Daiichi Sankyo Company, Limited - Deltanoid Pharmaceuticals Inc. - Diabetica Limited - DiscoveryBiomed, Inc. - Eisai Co., Ltd. - Eli Lilly and Company - Esperion Therapeutics, Inc. - Euroscreen S.A. - F. Hoffmann-La Roche Ltd. - FibroGen, Inc. For more information visit http://www.researchandmarkets.com/research/4fs2cn/obesity
AMBX: (), AMGN: 149.42 (-1.23), LLY: 72.57 (-0.71), BMY: 71.25 (+0.29), ESPR: 16.41 (-0.93), AZN: 28.64 (+0.22), FGEN: 15.68 (-0.27), ARNA: 1.87 (-0.03)
Crohn's Disease (Regional Enteritis) - Pipeline Review Report H2 2015
M2 - Tue Feb 09, 8:23AM CST
Research and Markets (http://www.researchandmarkets.com/research/crzbr7/crohns_disease) has announced the addition of the "Crohn's Disease (Regional Enteritis) - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Multiple Myeloma (Kahler Disease), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Crohn's Disease (Regional Enteritis)and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Crohn's Disease (Regional Enteritis)Overview - Therapeutics Development - Pipeline Products for Crohn's Disease (Regional Enteritis)- Overview - Pipeline Products for Crohn's Disease (Regional Enteritis)- Comparative Analysis - Crohn's Disease (Regional Enteritis)- Therapeutics under Development by Companies - Crohn's Disease (Regional Enteritis)- Therapeutics under Investigation by Universities/Institutes - Crohn's Disease (Regional Enteritis)- Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Crohn's Disease (Regional Enteritis)- Products under Development by Companies - Crohn's Disease (Regional Enteritis)- Products under Investigation by Universities/Institutes - Crohn's Disease (Regional Enteritis)- Companies Involved in Therapeutics Development Companies Mentioned - Sample List - 4D Pharma Plc - 4SC AG - AB Science SA - AbbVie Inc. - Alba Therapeutics Corporation - Alfa Wassermann S.p.A - Allozyne, Inc. - Altheus Therapeutics, Inc. - Amgen Inc. - Ampio Pharmaceuticals, Inc. - Arena Pharmaceuticals, Inc. - Avaxia Biologics, Inc. - BioAtla, LLC - BIOCAD - BioLingus AG - Bionovis SA - BioTherapeutics Inc. - Boehringer Ingelheim GmbH - Calypso Biotech SA - Celgene Corporation - Celltrion, Inc. - ChemoCentryx, Inc. - ChironWells GmbH - Chong Kun Dang Pharmaceutical Corp. - CLL Pharma - Commence Bio, Inc. - Daiichi Sankyo Company, Limited - DBV Technologies S.A. - Eisai Co., Ltd. - Eli Lilly and Company - Emergent BioSolutions Inc. - Enterome Bioscience SA - Enzo Biochem, Inc. - Epirus Biopharmaceuticals, Inc. - F. Hoffmann-La Roche Ltd. For more information visit http://www.researchandmarkets.com/research/cr...ns_disease
EBS: 39.32 (unch), AMGN: 149.42 (-1.23), AMPE: 3.33 (+0.11), LLY: 72.57 (-0.71), ENZ: 5.68 (+0.01), CCXI: 4.48 (-0.09), ABBV: 59.98 (-0.13), ARNA: 1.87 (-0.03), CELGZ: 1.44 (-0.01)
Head And Neck Cancer Therapeutics Pipeline Review, H2 2015
M2 - Tue Feb 09, 6:35AM CST
Research and Markets (http://www.researchandmarkets.com/research/bls9lh/head_and_neck) has announced the addition of the "Head And Neck Cancer - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Head And Neck Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Head And Neck Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Head And Neck Cancer Overview - Therapeutics Development - Pipeline Products for Head And Neck Cancer - Overview - Pipeline Products for Head And Neck Cancer - Comparative Analysis - Head And Neck Cancer - Therapeutics under Development by Companies - Head And Neck Cancer - Therapeutics under Investigation by Universities/Institutes - Head And Neck Cancer - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Head And Neck Cancer - Products under Development by Companies - Head And Neck Cancer - Products under Investigation by Universities/Institutes - Head And Neck Cancer - Companies Involved in Therapeutics Development - 4SC AG - AB Science SA - AbbVie Inc. - Acceleron Pharma, Inc. - Advaxis, Inc. - Alchemia Limited - Altor BioScience Corporation - Ambrx, Inc. - Amgen Inc. - ANP Technologies, Inc. - arGEN-X BV - ArQule, Inc. - Ascenta Therapeutics, Inc. - Astellas Pharma Inc. - Astex Pharmaceuticals, Inc. - AstraZeneca Plc - ATLAB Pharma SAS - AVEO Pharmaceuticals, Inc. - Bayer AG - Bexion Pharmaceuticals, LLC. - BIND Therapeutics, Inc. - Bio-Path Holdings, Inc. - BioDiem Ltd - Bionovis SA - Biotest AG - Boehringer Ingelheim GmbH - Boston Biomedical, Inc. - Bristol-Myers Squibb Company - CEL-SCI Corporation - Celgene Corporation - Cell Medica Limited - Cellceutix Corporation - Celldex Therapeutics, Inc. - Celltrion, Inc. - Centrose LLC - Cristal Therapeutics - Critical Outcome Technologies Inc. - CTI BioPharma Corp. - CytomX Therapeutics, Inc. - Daiichi Sankyo Company, Limited - EcoBiotics Limited For more information visit http://www.researchandmarkets.com/research/bl...d_and_neck
CVM: 0.46 (-0.01), AMBX: (), CLDX: 4.46 (+0.05), ARQL: 1.75 (unch), CTIC: 0.40 (-0.01), CTMX: 9.63 (+0.19), ABBV: 59.98 (-0.13), XLRN: 33.73 (-1.14), ADXS: 8.38 (-0.13), AMGN: 149.42 (-1.23), BIND: 0.44 (-0.02), BMY: 71.25 (+0.29), BPTH: 2.18 (+0.20), AZN: 28.64 (+0.22), AVEO: 0.98 (-0.03), CELGZ: 1.44 (-0.01)
Dyslipidemia Pipeline Review, H2 2015
M2 - Fri Feb 05, 6:27AM CST
Research and Markets (http://www.researchandmarkets.com/research/bbj35n/dyslipidemia) has announced the addition of the "Dyslipidemia - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Dyslipidemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Dyslipidemia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Dyslipidemia Overview - Therapeutics Development - Pipeline Products for Dyslipidemia - Overview - Pipeline Products for Dyslipidemia - Comparative Analysis - Dyslipidemia - Therapeutics under Development by Companies - Dyslipidemia - Therapeutics under Investigation by Universities/Institutes - Dyslipidemia - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Dyslipidemia - Products under Development by Companies - Dyslipidemia - Products under Investigation by Universities/Institutes - Dyslipidemia - Companies Involved in Therapeutics Development (Partial List) - Acasti Pharma Inc. - Allergan Plc - Alnylam Pharmaceuticals, Inc. - Amgen Inc. - Arbutus Biopharma Corporation - Arisaph Pharmaceuticals, Inc. - Astellas Pharma Inc. - AstraZeneca Plc - AtheroNova Inc. - BASF SE - BCWorld Pharm Co. Ltd. - Cadila Pharmaceuticals Ltd. - Cardax Pharmaceuticals, Inc. - Catabasis Pharmaceuticals, Inc. - Cerenis Therapeutics Holding SA - Chong Kun Dang Pharmaceutical Corp. - CJ HealthCare Corp. - Connexios Life Sciences Pvt. Ltd. - CymaBay Therapeutics, Inc. - Daewoong Pharmaceutical Co., Ltd. - Daiichi Sankyo Company, Limited - Debiopharm International S.A. - Eli Lilly and Company - Gemphire Therapeutics Inc. - Genfit SA - GlaxoSmithKline Plc - HanAll Biopharma Co., Ltd. - Hanmi Pharmaceuticals, Co. Ltd. - Huons Co., Ltd. - Hyundai Pharmaceutical Co., Ltd. - Innovent Biologics, Inc. - IPCA Laboratories Limited - Isis Pharmaceuticals, Inc. - Jeil Pharmaceutical Co., Ltd. - Jenrin Discovery, Inc. For more information visit http://www.researchandmarkets.com/research/bb...slipidemia
AMGN: 149.42 (-1.23), LLY: 72.57 (-0.71), GSK: 41.65 (+0.16), AGN: 231.55 (-3.71), ABUS: 3.17 (-0.09), ACST: 1.47 (-0.04), ISIS: 57.56 (-0.28), AZN: 28.64 (+0.22), CBAY: 1.69 (-0.06)
Cancer Pain Pipeline Review, H2 2015
M2 - Fri Feb 05, 4:26AM CST
Research and Markets (http://www.researchandmarkets.com/research/3tjd78/cancer_pain) has announced the addition of the "Cancer Pain - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Cancer Pain, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cancer Pain and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Cancer Pain Overview - Therapeutics Development - Pipeline Products for Cancer Pain - Overview - Pipeline Products for Cancer Pain - Comparative Analysis - Cancer Pain - Therapeutics under Development by Companies - Cancer Pain - Therapeutics under Investigation by Universities/Institutes - Cancer Pain - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Cancer Pain - Products under Development by Companies - Cancer Pain - Products under Investigation by Universities/Institutes - Cancer Pain - Companies Involved in Therapeutics Development - Amgen Inc. - Amorsa Therapeutics Inc. - AngioChem Inc. - Aphios Corporation - AstraZeneca Plc - BCN Peptides, S.A. - Benitec Biopharma Limited - BioDelivery Sciences International, Inc. - ChironWells GmbH - Daiichi Sankyo Company, Limited - Fujimoto Pharmaceutical Corporation - Grunenthal GmbH - GW Pharmaceuticals Plc - Hisamitsu Pharmaceutical Co., Inc. - Immupharma Plc - IntelGenx Corp. - Kolon Life Science, Inc. - Nektar Therapeutics - Neurocentrx Pharma Ltd. - Orion Oyj - Pain Therapeutics, Inc. - Pfizer Inc. - Pharmaleads - PsychoGenics, Inc. - Recordati S.p.A. - Ribomic Inc. - Virobay Inc. - WEX Pharmaceuticals Inc. - Winston Pharmaceuticals, Inc. - Zynerba Pharmaceuticals, Inc. For more information visit http://www.researchandmarkets.com/research/3t...ancer_pain
BDSI: 2.44 (+0.08), PFE: 34.75 (+0.25), AMGN: 149.42 (-1.23), ZYNE: 7.37 (-0.10), NKTR: 14.98 (-0.23), AZN: 28.64 (+0.22), VBAY: (), PTIE: 2.07 (-0.01)
Global Influenza A Infections Clinical Trials Review, H2, 2015
M2 - Thu Feb 04, 5:30AM CST
Research and Markets (http://www.researchandmarkets.com/research/2qjxfz/influenza_a) has announced the addition of the "Influenza A Infections Global Clinical Trials Review, H2, 2015" report to their offering. Influenza A Infections Global Clinical Trials Review, H2, 2015" provides an overview of Influenza A Infections clinical trials scenario. This report provides top line data relating to the clinical trials on Influenza A Infections. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). Key Topics Covered: - List of Tables - List of Figures - Report Guidance - Clinical Trials by Region - Clinical Trials and Average Enrollment by Country - Top Five Countries Contributing to Clinical Trials in Asia-Pacific - Top Five Countries Contributing to Clinical Trials in Europe - Top Countries Contributing to Clinical Trials in North America - Top Countries Contributing to Clinical Trials in Middle East and Africa - Top Five Countries Contributing to Clinical Trials in Central and South America - Clinical Trials by G7 Countries: Proportion of Influenza A Infections to Infectious Disease Clinical Trials - Clinical Trials by Phase in G7 Countries - Clinical Trials in G7 Countries by Trial Status - Clinical Trials by E7 Countries: Proportion of Influenza A Infections to Infectious Disease Clinical Trials - Clinical Trials by Phase in E7 Countries - Clinical Trials in E7 Countries by Trial Status - Clinical Trials by Phase - In Progress Trials by Phase - Clinical Trials by Trial Status - Clinical Trials by End Point Status - Subjects Recruited Over a Period of Time - Clinical Trials by Sponsor Type - Prominent Sponsors - Top Companies Participating in Influenza A Infections Therapeutics Clinical Trials - Prominent Drugs - Latest Clinical Trials News on Influenza A Infections - Clinical Trial Profile Snapshots Companies Mentioned - GlaxoSmithKline Plc - Novartis AG - Sanofi - Johnson & Johnson - AstraZeneca Plc - Microgen Scientific Industrial Company for Immunobiological Medicines - F. Hoffmann-La Roche Ltd. - Daiichi Sankyo Company, Limited - Altimmune, Inc. - Nanotherapeutics, Inc. For more information visit http://www.researchandmarkets.com/research/2q...nfluenza_a
JNJ: 116.18 (-0.36), AZN: 28.64 (+0.22), GSK: 41.65 (+0.16), NVS: 79.46 (+0.79)
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Pipeline Review, H2 2015
M2 - Thu Feb 04, 5:02AM CST
Research and Markets (http://www.researchandmarkets.com/research/trfcb9/acute_lymphocytic) has announced the addition of the "Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Overview - Therapeutics Development - Pipeline Products for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Overview - Pipeline Products for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Comparative Analysis - Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Therapeutics under Development by Companies - Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Therapeutics under Investigation by Universities/Institutes - Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Products under Development by Companies - Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Products under Investigation by Universities/Institutes - Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Companies Involved in Therapeutics Development Companies Mentioned - Partial List - 4SC AG - AbbVie Inc. - Actinium Pharmaceuticals, Inc. - Affimed Therapeutics AG - Altor BioScience Corporation - Amgen Inc. - Atara Biotherapeutics, Inc. - Baxalta Incorporated - Bellicum Pharmaceuticals, Inc. - Bexion Pharmaceuticals, LLC. - Bio-Path Holdings, Inc. - BioSight Ltd. - Bristol-Myers Squibb Company - Calithera Biosciences, Inc. - Cantargia AB - Celator Pharmaceuticals, Inc. - Cellectis S.A. - Cellular Biomedicine Group, Inc. - Ceronco Biosciences - Constellation Pharmaceuticals, Inc. - Cyclacel Pharmaceuticals, Inc. - Daiichi Sankyo Company, Limited - DiNonA Inc. - Effimune SAS - Eli Lilly and Company - Epirus Biopharmaceuticals, Inc. - EpiZyme, Inc. - Erytech Pharma SA - Eureka Therapeutics, Inc. - Fate Therapeutics, Inc. - Formula Pharmaceuticals, Inc. - Gamida Cell Ltd. - GlaxoSmithKline Plc - Hangzhou Minsheng Pharmaceutical Group Co.,Ltd For more information visit http://www.researchandmarkets.com/research/tr...ymphocytic
FATE: 1.89 (-0.11), AMGN: 149.42 (-1.23), EPZM: 10.92 (-0.04), LLY: 72.57 (-0.71), ATRA: 21.56 (+0.50), GSK: 41.65 (+0.16), BMY: 71.25 (+0.29), ATNM: 1.75 (-0.02), CYCC: 5.39 (+0.27), BLCM: 12.49 (-0.33), BPTH: 2.18 (+0.20), CALA: 4.24 (-0.02), ABBV: 59.98 (-0.13), BXLT: 46.02 (-0.18), CBMG: 14.30 (-0.85)
